Gene · 22925
Papers2,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Serum PLA2R-negative, biopsy-proven PLA2R-positive primary membranous nephropathy in a dichorionic-diamniotic twin pregnancy. | BMJ Case Rep | 2026 | 42498317 | PubTator, text mining | PubMed |
| Clinical effect of obinutuzumab in the treatment of idiopathic membranous nephropathy. | Am J Transl Res | 2026 | 42491171 | PubTator, text mining | PubMed |
| Efficacy of immunosuppressive therapy in low-risk and intermediate- risk idiopathic membranous nephropathy patients : a 2-year follow-up study. | BMC Nephrol | 2026 | 42481971 | PubTator, text mining | PubMed |
| Lung cancer-associated membranous nephropathy with positive anti-PLA2R autoantibodies: a case report. | Pan Afr Med J | 2026 | 42465821 | PubTator, text mining | PubMed |
| Renal vein thrombosis with inferior vena cava extension in PLA2R-positive membranous nephropathy: A radiological mimic of acute pyelonephritis. | Radiol Case Rep | 2026 | 42437135 | PubTator, text mining | PubMed |
| Artificial intelligence in membranous nephropathy: transforming clinical management toward precision medicine. | Front Med (Lausanne) | 2026 | 42433995 | PubTator, text mining | PubMed |
| Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients. | Front Immunol | 2026 | 42433359 | PubTator, text mining | PubMed |
| Contemporary review of primary membranous nephropathy. | Front Immunol | 2026 | 42404886 | PubTator, text mining | PubMed |
| Concurrent Mantle Cell Lymphoma and Paraneoplastic Membranous Nephropathy. | Kidney Med | 2026 | 42375693 | PubTator, text mining | PubMed |
| Treatment of High-Risk Idiopathic Membranous Nephropathy with Huaier Granules and RASi: A Case Series. | Int Med Case Rep J | 2026 | 42367349 | PubTator, text mining | PubMed |
| Animal models of idiopathic membranous nephropathy: Recent advances and future perspectives. | Animal Model Exp Med | 2026 | 42367084 | PubTator, text mining | PubMed |
| The need for kidney biopsy in suspected primary membranous nephropathy with typical clinical presentation and positive anti-PLA2R antibodies. | Med Clin (Barc) | 2026 | 42365808 | PubTator, text mining | PubMed |
| Diagnostic performance of time-resolved fluoroimmunoassay based anti-phospholipase A2 receptor antibody detection for primary membranous nephropathy. | Sci Rep | 2026 | 42343095 | PubTator, text mining | PubMed |
| Risk stratification guided treatment and outcomes of pediatric membranous nephropathy. | Pediatr Nephrol | 2026 | 42340439 | PubTator, text mining | PubMed |
| Idiopathic multiple castleman disease case combined with severe neuropathy, Sjogren's syndrome and membrane nephropathy treated by rituximab: a case report and literature review. | Front Immunol | 2026 | 42327772 | PubTator, text mining | PubMed |
| A Clinicopathologic Study of Neural Epidermal Growth Factor-Like 1-Associated Membranous Nephropathy in a Chinese Cohort. | Kidney Int Rep | 2026 | 42318536 | PubTator, text mining | PubMed |
| IgM Hyposialylation Modulates Podocyte Vulnerability in Patients With Idiopathic Nephrotic Syndrome. | Kidney Int Rep | 2026 | 42318532 | PubTator, text mining | PubMed |
| Membranous nephropathy secondary to very early-onset inflammatory bowel disease in a 3-year-old boy: case report. | CEN Case Rep | 2026 | 42315775 | PubTator, text mining | PubMed |
| Quantitative serological detection of NELL1 autoantibodies in membranous nephropathy. | Kidney Int | 2026 | 42315018 | PubTator, text mining | PubMed |
| Single-cell transcriptomic analysis reveals the T lymphocyte microenvironment and identifies HOPX as a hub gene in membranous nephropathy. | Gene | 2026 | 42309401 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/22925/papers?page=2